Efficacy and Safety of Atazanavir in Patients with End-Stage Liver Disease
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
No data are available on the use of atazanavir (ATV) in patients with end-stage liver disease (ESLD), and guidelines discourage its use in this setting. The objective of our study was to evaluate the efficacy and safety of unboosted ATV in patients infected with HIV and suffering from ESLD who had been screened for orthotopic liver transplantation (OLTx).
Patients and Methods:
This was a single-arm, 24-week pilot study. Atazanavir-naïve patients undergoing a highly active antiretroviral therapy were switched to ATV 400 mg daily plus two non-thymidine nucleoside reverse transcriptase inhibitors.
Fifteen patients (ten males and five females, age range 36–59 years) were enrolled in the study. Of these, 11 (73%) had a baseline CD4 cell count > 200 μl–1, and 12 had undetectable plasma HIV-RNA. 12 subjects (80%) were able to remain on ATV until week 24 (n = 10) or transplantation (n = 2). At the end of the study, the median CD4 cell count was 340 μl–1 , and nine of the ten patients had undetectable RNA. During the study period, two patients received a transplant, two died of intracerebral hemorrhage and lactic acidosis, respectively, and one discontinued ATV. Among the ten patients completing the 24-week study, no significant changes from baseline were observed for most of the liver function markers, with the exception of unconjugated bilirubin (from 1.15 mg/dl to 1.32 mg/dl, p = 0.047).
Unboosted ATV treatment did not worsen liver disease and was able to maintain or gain immunovirological eligibility for OLTx in all patients, with a limited effect on unconjugated bilirubin. These results suggest that ATV is an easy-to-use drug in patients with ESLD.
- Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE: Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation. Lancet 1997; 350: 1425–1431. CrossRef
- Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, Rey C, Abad MA, Rodriguez M, Sales Gilabert M, Gonzalez F, Miron P, Caruz A, Relimpio F, Torronteras R, Leal M, Lissen E: Human immunodeficiency virus infection modifies the natural history of chronic parenterallyacquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1–5. CrossRef
- Telfer PT, Brown D, Devereux H, Lee CA, DuSheiko GM: HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients. Br J Haematol 1994; 88: 397–399. CrossRef
- Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492–497. CrossRef
- Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J: Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 1–4. CrossRef
- Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G: Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207–1214. CrossRef
- Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J: Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1467–1471. CrossRef
- Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, Quiros-Roldan E, Zanini B, Casari S, Carosi G: Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24: 211–217.
- Wyles DL, Gerber JG: Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40: 174–181. CrossRef
- The Panel on Clinical Practices for Treatment of HIV infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (29 Jan 2008). Available at: http://aidsinfo.nih.gov/Guidelines. Accessed 23 Feb 2008.
- Aube C, Oberti F, Korali N, Namour MA, Loisel D, Tanguy JY, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Rifflet H, Maiga MY, Penneau-Fontbonne D, Caron C, Cales P: Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30: 472–478. CrossRef
- Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D: Severe liver fibrosis or cirrhosis: accuracy of US for detection-analysis of 300 cases. Radiology 2003; 227: 89–94. CrossRef
- Di Lelio A, Cestari C, Lomazzi A, Beretta L: Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology 1989; 172: 389–392.
- Kaul S, Bassi K, Damle B, Xie J, Gale J, Kearne B, Hanna. Abstract 43rd Interscience Conf Antimicrobial Agents Chemotherapy. Abstract A-1616 2003.
- Cahn P, Piliero P, Giordano M, Thiry A, Schnitman S. Abstract 42nd Interscience Conf Antimicrobial Agents Chemotherapy. Abstract H-1730 2002.
- Brouwer KLR, Dukes GE, Powell JR: Influence of liver function on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics, principles of therapeutic drug monitoring. 3rd edition Appl Therapeutics, Vancouver 1992, pp 6.1–6.59.
- Efficacy and Safety of Atazanavir in Patients with End-Stage Liver Disease
Volume 37, Issue 3 , pp 250-255
- Cover Date
- Print ISSN
- Online ISSN
- Urban and Vogel
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Dept. of Internal Medicine and Medical Specialties, Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100, Modena, Italy
- 2. Dept. of Infectious Diseases, University of Turin, Turin, Italy
- 3. Dept. of General Surgery, Liver and Multivisceral Transplant Centre, University of Modena and Reggio Emilia, Modena, Italy
- 4. Dept. of Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy
- 5. Division of Toxicology and Clinical Pharmacology, University of Modena and Reggio Emilia, Modena, Italy